Drug application
SUCLEAR (MAGNESIUM SULFATE, POLYETHYLENE GLYCOL 3350, POTASSIUM CHLORIDE and 4 more)
Drugs@FDA NDA 203595 · BRAINTREE LABS
Key facts
| Drug name | SUCLEAR |
|---|---|
| Active ingredients | MAGNESIUM SULFATE, POLYETHYLENE GLYCOL 3350, POTASSIUM CHLORIDE, POTASSIUM SULFATE, SODIUM BICARBONATE, SODIUM CHLORIDE, SODIUM SULFATE |
| Application type | NDA |
| Application number | 203595 |
| Company | BRAINTREE LABS |
| Dosage forms | SOLUTION, ORAL |
| Strength | 1.6GM/BOT,3.13GM/BOT,17.5GM/BOT,N/A,N/A,N/A,N/A;N/A,N/A,N/A,210GM,0.74GM,2.86GM,5.6GM **Federal Register determination that product was not discontinued or… |
| Marketing status | Discontinued |
| Reference listed drug | Yes |
| Latest submission class | Type 4 - New Combination |
| Latest submission status date | Jan 18, 2013 |
At a glance
- 1–9 Submissions
- 1–9 Supplements
- 1–9 Label versions
- 1–9 Products
- None Therapeutic equivalents
- Yes FDA letters on file
- Yes FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: